Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding BioCardia’s regulatory trail can feel like navigating a clinical protocol. Trial spending, CardiAMP milestones, and executive stock sales are spread across hundreds of pages of SEC exhibits. If finding BioCardia insider trading Form 4 transactions or isolating cash-burn disclosures in a 10-Q has cost you hours, you’re not alone.
Stock Titan turns that problem on its head. Our platform delivers BioCardia SEC filings explained simply: AI-powered summaries strip the jargon from every 10-K, 10-Q, 8-K, and Form 4 the moment they hit EDGAR. Need the BioCardia quarterly earnings report 10-Q filing? We highlight trial expense trends and funding runway. Tracking leadership moves? Receive BioCardia Form 4 insider transactions real-time with context on option grants, sales tied to secondary offerings, and other BioCardia executive stock transactions Form 4.
Investors use these insights to gauge dilution risk ahead of pivotal CardiAMP readouts, monitor material events with BioCardia 8-K material events explained, and benchmark progress through each proxy season. Our coverage spans every document type—from a BioCardia annual report 10-K simplified for pipeline updates to the BioCardia proxy statement executive compensation that clarifies how management is incentivized. With real-time alerts, AI-driven plain-English explanations, and side-by-side BioCardia earnings report filing analysis, understanding BioCardia SEC documents with AI becomes straightforward. No more paging through PDFs; the critical data points are surfaced for decisive action.
Simon H. Stertzer, a director of BioCardia, Inc. (BCDA), reported purchases and related holdings on Form 4. He participated in a public offering that closed on 09/19/2025, purchasing 398,400 shares of common stock at $1.25 per share and receiving 398,400 warrants exercisable into one share each at $1.25. The warrants are dated 09/19/2025 and expire 09/20/2027. After the reported transactions the filing shows 591,054 shares beneficially owned indirectly by entities tied to the reporting person, and several pre-existing holdings across trusts and LLCs are disclosed. The Form 4 is signed by power of attorney on 09/23/2025.
BioCardia insider purchase reported on Form 4: Director Andrew Scott (reporting as Andy Blank Revocable Living Trust) purchased 288,000 shares of common stock and received 288,000 warrants on 09/19/2025 at a price of $1.25 per share/warrant bundle. After the transaction the reporting person beneficially owned 634,023 shares (direct/indirect holdings) and held warrants exercisable into 288,000 shares expiring 09/20/2027. The filing notes the shares are held in a revocable trust for which the reporting person is trustee. The Form 4 was signed by power of attorney on 09/23/2025.
Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.
Lincoln Alternative Strategies LLC reported beneficial ownership of 800,000 shares of BioCardia, Inc. common stock, representing 7.54% of the outstanding shares based on 10,608,734 shares outstanding as of September 19, 2025. The filing lists sole voting and dispositive power over all 800,000 shares and indicates the holder is organized in Delaware. The filing includes a certification that the securities were not acquired to change or influence control of the issuer. Contact and address details for the issuer and filer are provided in the statement.
BioCardia, Inc. completed a registered offering on September 19, 2025, selling 4,800,000 shares of common stock together with warrants to purchase up to 4,800,000 shares at a combined price of $1.25 per share and warrant, generating approximately $6.0 million in gross proceeds. Certain directors and executive officers purchased 734,400 shares and warrants for roughly $0.9 million. The company expects net proceeds of about $5.1 million after placement agent fees and offering expenses. Each warrant is exercisable at $1.25, immediately exercisable, and expires September 20, 2027, subject to customary anti-dilution adjustments and beneficial ownership exercise limits (default 4.99% or elective 9.99% with notice). The Purchase Agreements include customary representations, indemnities and closing conditions, and contain lock-up and variable-rate transaction restrictions through November 18, 2025 and March 19, 2026, respectively, which the placement agent may waive.
FAQ
What is the current stock price of Biocardia (BCDA)?
What is the market cap of Biocardia (BCDA)?
